This invention describes construction and initial functional testing of engineered chimeric antigen receptors transduced into human T-cells (CAR-T cells) for selective killing of melanocytes and melanoma cells.
Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.